logo

Altimmune Inc. (ALT)



Trade ALT now with
  Date
  Headline
6/30/2020 7:11:18 AM Altimmune Announces Dosing Of First Patient In Phase 1b Clinical Trial Of NasoShield
6/29/2020 7:40:16 AM Altimmune Gets Award From DoD To Fund Phase 1/2 Clinical Trial Of T-COVID
6/22/2020 7:09:02 AM Altimmune Says FDA Cleared IND Application To Conduct Phase 2 Trial Of HepTcell
6/1/2020 7:13:19 AM Altimmune Says FDA Authorized Co. To Proceed With Clinical Trial Of T-COVID
3/27/2020 7:28:43 AM Altimmune 2019 Net Loss Attributed $20.97 Mln Or $1.60 Per Share
1/23/2020 7:13:48 AM Altimmune Announces Positive Results For ALT-702 In Preclinical Model Of Colorectal Cancer
9/9/2019 7:09:54 AM Altimmune Appoints Scott Harris As Chief Medical Officer
7/15/2019 7:07:58 AM Altimmune Announces Closing Of Acquisition Of Spitfire Pharma
7/9/2019 7:19:11 AM Altimmune To Acquire Spitfire Pharma
7/9/2019 7:05:14 AM Altimmune Agrees To Acquire Spitfire Pharma; Transaction To Close During July
6/10/2019 8:10:13 AM Altimmune Reports Pre-IND Meeting For HepTcell; Phase 2 Trial To Start In 2020
6/5/2019 8:12:57 AM Altimmune Receives Addl Patent Protection For Its HepTcell And ALT-702 Programs
3/19/2019 7:09:04 AM Altimmune Announces Positive Results From NasoVAX Extension Study
1/29/2019 8:08:42 AM Altimmune Announces Presentation Of HepTcell Phase 1 Results At International Liver Congress™ In Vienna, Austria